Upcoming Events

The Reagan-Udall Foundation for the FDA will be conducting a series of six closed-door virtual roundtable conversations with biosimilar developers to explore emerging areas of regulatory science and to create a space for active discussion and exploration between FDA and biosimilar developers.
- Join the Food and Drug Administration (FDA) and the Reagan-Udall Foundation for the FDA for the fifth Online Controlled Substances Summit.
Implementing the RAISE Action Framework Virtual Public Meeting July 16, 2024 | 2-3pm (eastern)  

Past Events

The Reagan-Udall Foundation for the FDA, in collaboration with the FDA, hosted a hybrid public workshop on "Understanding Current Use of Ketamine for Emerging Areas of Therapeutic Interest."
The Reagan-Udall Foundation for the FDA, in collaboration with the Food and Drug Administration (FDA), hosted a public webinar as part of a series of webinars for FDA-issued guidance related to real-world evidence (RWE).
The Reagan-Udall Foundation for the FDA, in collaboration with FDA’s Rare Diseases Team within the Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine; Office of New Drugs; Center for Drug Evaluation and Research and the National Institutes of Health’s Division of Rare Diseases Research Innovation within the National Center for Advancing Translational Sciences, is hosting a public workshop.
Each year, the Reagan-Udall Foundation for the FDA conducts an annual public meeting to discuss its activities in support of the U.S. Food and Drug Administration.
Qualifying Biomarkers to Support Rare Disease Regulatory Pathways
- Advancing Psychedelic Clinical Study DesignVirtual Public Meeting Day 1: January 31, 2024 | 10am-2pm (eastern)
Front-of-Package Nutrition LabelingVirtual Public Meeting
Integrating Clinical Studies Into Health Care Delivery: Post-Market Evidence Generation for Medical ProductsVirtual Public Meeting
Strategies for Improving Public Understanding of FDA-Regulated Products Virtual Public Meeting